Two Rare Cases of Tumor Calcinosis

Authors

  • Shanthisree Edara Institute of Endocrinology, Diabetes, Thyroid and Osteoporosis Disorders, Sakra World Hospital, Bangalore, Karnataka State, India Author
  • Sherin Philip Institute of Endocrinology, Diabetes, Thyroid and Osteoporosis Disorders, Sakra World Hospital, Bangalore, Karnataka State, India Author
  • Sushma Rani Raju Department of Nephrology, Sakra World Hospital, Bangalore, Karnataka State, India Author
  • Venu Madhav Reddy Department of Nephrology, Sakra World Hospital, Bangalore, Karnataka State, India Author
  • Anisha Tandon Department of Radiology, Sakra World Hospitals, Bangalore, Karnataka State, India Author
  • Harinarayan C V Institute of Endocrinology, Diabetes, Thyroid and Osteoporosis Disorders, Sakra World Hospital, Bangalore, Karnataka State, India; Saveetha Institute of Medical and Technical Sciences University, Saveetha Medical College, Chennai, India Author

DOI:

https://doi.org/10.47363/JONE/2022(2)112

Keywords:

Tumor Calcinosis, Hyperphosphatemia, FGF 23, GaLNAc-transferase 3 (GALNT3), Klotho, Galnt3

Abstract

Tumour calcinosis is a rare disorder of phosphate metabolism. Familial tumour calcinosis is caused due to gene mutations affecting the activity of FGF23, a phosphoturic hormone. The presentation is hyperphosphatemia and calcified deposits in the periarticular regions. Surgery though being the mainstay of treatment, recurrence is often common without additional treatment. Phosphate restricted diet and phosphate binder before and after surgery would be beneficial. We present two cases of tumour calcinosis with hyperphosphatemia and calcified deposits, evaluated and followed up. We discuss various treatment options available for this rare condition.

Author Biographies

  • Shanthisree Edara, Institute of Endocrinology, Diabetes, Thyroid and Osteoporosis Disorders, Sakra World Hospital, Bangalore, Karnataka State, India

    Institute of Endocrinology, Diabetes, Thyroid and Osteoporosis Disorders, Sakra World Hospital, Bangalore, Karnataka State, India.

  • Sherin Philip, Institute of Endocrinology, Diabetes, Thyroid and Osteoporosis Disorders, Sakra World Hospital, Bangalore, Karnataka State, India

    Institute of Endocrinology, Diabetes, Thyroid and Osteoporosis Disorders, Sakra World Hospital, Bangalore, Karnataka State, India.

  • Sushma Rani Raju, Department of Nephrology, Sakra World Hospital, Bangalore, Karnataka State, India

    Department of Nephrology, Sakra World Hospital, Bangalore, Karnataka State, India.

  • Venu Madhav Reddy, Department of Nephrology, Sakra World Hospital, Bangalore, Karnataka State, India

    Department of Nephrology, Sakra World Hospital, Bangalore, Karnataka State, India.

  • Anisha Tandon, Department of Radiology, Sakra World Hospitals, Bangalore, Karnataka State, India

    Department of Radiology, Sakra World Hospitals, Bangalore, Karnataka State, India.

  • Harinarayan C V, Institute of Endocrinology, Diabetes, Thyroid and Osteoporosis Disorders, Sakra World Hospital, Bangalore, Karnataka State, India; Saveetha Institute of Medical and Technical Sciences University, Saveetha Medical College, Chennai, India

    Harinarayan C V, Institute of Endocrinology, Diabetes, Thyroid and Osteoporosis Disorders, Sakra World Hospitals, Bangalore 560103, Karnataka State, INDIA.

Downloads

Published

2025-12-02

Issue

Vol. 2 No. 2 (2022): Volume 2 Issue 2

Section

Articles